Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.71 |
| ▸ | FLT1 | P17948 | 14/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 12/20 | 0.71 |
| ▸ | KIT | P10721 | 11/20 | 0.71 |
| ▸ | CSF1R | P07333 | 2/20 | 0.59 |
| ▸ | FLT4 | P35916 | 2/20 | 0.59 |
| ▸ | CIT | O14578 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | HLA-A | P04439 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.58 |
| ▸ | FRK | P42685 | 1/20 | 0.58 |
| ▸ | CDK8 | P49336 | 1/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.58 |
| ▸ | STK3 | Q13188 | 1/20 | 0.58 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.58 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.58 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841142 | 1.00 | KDR (0.71) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL22680178 | 0.87 | KDR (0.68) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL22680325 | 0.85 | KDR (0.67) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL24997219 | 0.84 | FLT1 (0.49) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL905704 | 0.83 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL905586 | 0.83 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL6607263 | 0.82 | KDR (0.73) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL905612 | 0.82 | KDR (0.76) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL905634 | 0.81 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL905680 | 0.81 | KDR (0.76) | KDRFLT1PDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| CN-117355303-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| WO-2020232255-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-0970070-B1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6710047-B2 | INHIBIT THE ACTIVITY OF THE VEGF RECEPTOR TYROSINE KINASE AND THE GROWTH OF TUMOURS | NOVARTIS AG (CH) | 2004-03-23 | — | — | US | disclosed |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2003-10-09 | — | — | US | disclosed |
| US-6514974-B2 | 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine for example | NOVARTIS AG (CH) | 2003-02-04 | — | — | US | disclosed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | disclosed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| EP-0970070-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035958-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | KDR 10/4885FLT1 4/4885PDGFRB 124/4885 |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | KDR 4556/4885FLT1 4603/4885PDGFRB 4516/4885 |
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | KDR 4812/4885FLT1 4658/4885PDGFRB 4325/4885 |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | KDR 16/4885FLT1 4/4885PDGFRB 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.